MUC16 monoclonal antibody and uses thereof
US11773183B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 30, 2019 |
| Grant date | Oct 3, 2023 |
| Priority date | — |
| Expiry date | Mar 15, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2400/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present document describes an antibody or an antigen-binding fragment that bind to O-glycan mucin-type glycoprotein MUC16 comprising three variable heavy domain complementarity determining regions (CDR)(CDR H1, H2 and H3), and three variable lighy domain CDR (CDR L1, L2 and L3). The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells comprising the nucleic acid vectors, and methods of inhibiting tumor growth of a tumor expressing O-glycan mucin-type glycoprotein MUC16.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.